Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467023 | 0.94 | SIGMAR1 (1.00) | SIGMAR1KCNH2KDM4E | |
| SCHEMBL466979 | 0.88 | SIGMAR1 (0.88) | SIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL1903312 | 0.87 | SIGMAR1 (0.86) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL1896893 | 0.85 | SIGMAR1 (0.88) | SIGMAR1KCNH2 | |
| Oxalic Acid SCHEMBL1899223 | 0.83 | SIGMAR1 (0.91) | SIGMAR1KCNH2KDM4E | |
| SCHEMBL1896482 | 0.78 | SIGMAR1 (0.62) | SIGMAR1KCNH2 | |
| SCHEMBL467442 | 0.78 | SIGMAR1 (1.00) | SIGMAR1KCNH2 | |
| SCHEMBL466872 | 0.77 | SIGMAR1 (1.00) | SIGMAR1KCNH2KDM4E | |
| Oxalic Acid SCHEMBL1894175 | 0.77 | SIGMAR1 (0.88) | SIGMAR1KCNH2 | |
| Ammonia Solution, Strong SCHEMBL20608292 | 0.76 | SIGMAR1 (0.98) | SIGMAR1KCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463339-B1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | ESTEVE PHARMACEUTICALS SA (ES) | 2023-12-06 | — | — | EP | disclosed |
| US-20190142840-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-16 | — | — | US | disclosed |
| WO-2019068771-A1 | USE OF SIGMA RECEPTOR LIGANDS IN AGE-RELATED COGNITIVE IMPAIRMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-11 | — | — | WO | disclosed |
| EP-3463339-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018011169-A1 | USE OF SIGMA RECEPTOR LIGANDS IN POST-HERPETIC PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017211763-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211765-A1 | SIGMA LIGANDS FOR USE IN THE TREATMENT OF DIABETES AND METABOLIC SYNDROME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-12-14 | — | — | WO | disclosed |
| US-20170273948-A1 | USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2017-09-28 | — | — | US | disclosed |
| US-8470867-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-25 | — | — | US | disclosed |
| US-8314096-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-11-20 | — | — | US | disclosed |
| US-8293740-B2 | Sigma receptor inhibitors | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2012-10-23 | — | — | US | disclosed |
| EP-1781618-B1 | SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2012-10-03 | — | — | EP | disclosed |
| EP-2325174-A1 | Sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-05-25 | — | — | EP | disclosed |
| US-20100190780-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | disclosed |
| US-20100190790-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | disclosed |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2010-07-29 | — | — | US | disclosed |
| US-7696199-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-13 | — | — | US | disclosed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | disclosed |
| EP-1781618-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021462-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142840-A1 | USE OF SIGMA RECEPTOR LIGANDS IN CANCER | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 3544/4885KDM4E 4113/4885 |
| US-20100190790-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 1365/4885KDM4E 4559/4885 |
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 1365/4885KDM4E 4559/4885 |
| US-20170273948-A1 | USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS | SIGMAR1, OPRL1, OPRK1 | SIGMAR1 1/4885KCNH2 2571/4885KDM4E 4332/4885 |
| US-20100190781-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 1365/4885KDM4E 4559/4885 |
| US-20100190780-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885KCNH2 1365/4885KDM4E 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.